CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 329 enrolled
Drug / intervention
Trifecta™ Valvedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01593917
NCT01593917N/ACompleted

Long Term Follow Up Study of the St. Jude Medical Trifecta™ Valve

Abbott Medical Devices·observational·Posted May 8, 2012·Updated Feb 11, 2025

In Brief

An observational study evaluating Trifecta™ Valve for Aortic Valve Insufficiency and 3 related conditions. Completed, enrolled 329 participants across 11 sites in 2 countries.

Detailed Summary

The Trifecta™ LTFU Study is a single-arm, multi-center, prospective, non-randomized, post-market study conducted in the United States and Canada to collect long-term safety and effectiveness data through 10 years after implant of the Trifecta™ aortic bioprosthetic valve. The Trifecta™ is a tri-leaflet stented pericardial valve designed for supraannular placement in the aortic position. The Trifecta™ LTFU Study is an extension of the Trifecta™ Investigational Device Exemption (IDE) Study (NCT00475709) conducted to support United States Food and Drug Administration (FDA) approval of the Trifecta™ valve. All Trifecta™ LTFU Study subjects received Trifecta™ valve implants during participation in the Trifecta™ IDE study and subsequently consented to extended annual follow-up through 10 years under the Trifecta™ LTFU protocol.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesCanada, United States
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 8, 2012
Enrollment StartJul 2, 2012
Primary CompletionSep 26, 2019
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 14.2 years ago

Interventions

Trifecta™ Valvedevice

Aortic valve replacement with the Trifecta™ aortic bioprosthesis.